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Abstract: Age-related macular degeneration (AMD), akin to other common age-related 
diseases, has a complex pathogenesis and arises from the interplay of genes, environmental 
factors, and personal characteristics. The past decade has seen very significant strides towards 
identification of those precise genetic variants associated with disease. That genes encoding 
proteins of the (alternative) complement pathway (CFH, C2, CFB, C3, CFI) are major players 
in etiology came as a surprise to many but has already lead to the development of therapies 
entering human clinical trials. Other genes replicated in many populations ARMS2, APOE, 
variants near TIMP3, and genes involved in lipid metabolism have also been implicated in dis-
ease pathogenesis. The genes discovered to date can be estimated to account for approximately 
50% of the genetic variance of AMD and have been discovered by candidate gene approaches, 
pathway analysis, and latterly genome-wide association studies. Next generation sequencing 
modalities and meta-analysis techniques are being employed with the aim of identifying the 
remaining rarer but, perhaps, individually more significant sequence variations, linked to disease 
status. Complementary studies have also begun to utilize this genetic information to develop 
clinically useful algorithms to predict AMD risk and evaluate pharmacogenetics. In this article, 
contemporary commentary is provided on rapidly progressing efforts to elucidate the genetic 
pathogenesis of AMD as the field stands at the end of the first decade of the 21st century.
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Introduction
Individuals who develop age-related macular degeneration (AMD) lose central vision 
due to involvement of the macula, the central region of the retina specialized to 
distinguish fine detail, thus permitting activities such as reading, recognizing faces, 
and driving. Although several retinal layers are affected, vision is primarily lost when 
photoreceptors die. The term age-related maculopathy (ARM) describes the spectrum 
of age-related macular changes, from the early presence of a few small drusen (sub-
retinal lipid and protein-containing deposits which are the hallmark of the condition) 
to the most advanced stages with severe anatomic changes accompanied by vision 
loss.1,2 Patients with larger and more numerous drusen, often with advanced or visually 
significant ARM, are referred to as having AMD.3 Two advanced forms of the disease 
are recognized: “dry” or atrophic AMD (geographic atrophy), in which atrophy of the 
retinal pigment epithelium (RPE) results in untreatable progressive visual loss; and 
“wet” or neovascular AMD, characterized by the intraretinal invasion of vessels from 
the choroid, which usually bleed and form dense macular scars.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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One-and-three-quarter million individuals in the United 
States have the advanced, visually disabling form of AMD. 
More than seven million additional individuals have earlier 
retinal changes, placing them at high risk of developing 
advanced AMD. In those older than 75 years, the prevalence of 
advanced disease is approximately 8%, and 30% will develop 
degenerative macular changes consistent with earlier forms of 
the disease.4 With the expected increase in the number of older 
individuals in the population, it is predicted that the prevalence 
of AMD will increase by more than 50% by the year 2020, 
substantially increasing the health burden from AMD.5
Neovascular AMD is the cause of most cases of legal 
blindness. Symptoms may progress rapidly over days to 
weeks, with the major complaints being reduced acuity and 
distortion. Clinical examination typically reveals the presence 
of subretinal fluid and hemorrhage. Intra- and subretinal 
edema and hemorrhage may also be accompaniments.6,7 As the 
disease progresses, retinal gliosis may develop, together with 
permanent visual loss. Neovascularization is best delineated 
on fluorescein angiography where several patterns are well 
recognized. The mainstay of clinical evaluation has recently 
become optical coherence tomography, which has enabled 
very sensitive detection of retinal and subretinal fluid and 
therefore guides the need for treatment with intravitreal 
anti-vascular endothelial growth factor (anti-VEGF) agents.8 
Geographic atrophy is characterized by enlarging area(s) 
of outer retinal atrophy (retinal pigment epithelium and 
photoreceptors) in the macular region that typically and 
inexorably expands to affect the fovea.
Extensive epidemiologic and genetic analyses have 
lead to the conclusion that AMD, like many other chronic 
age-related diseases, results from the interplay of multiple 
environmental and genetic factors, which in combination 
account for development of the phenotype. The condition 
is strongly age-related, and tobacco smoking is the most 
consistent and modifiable significant risk factor.9–11 Other 
environmental risk factors that have been reported include 
cardiovascular disease,12–14 hypertension,15,16 high body mass 
index,17 and low education level.18
Genetic susceptibility and AMD
It is now beyond question that genes play a significant etio-
logical role in AMD.19,20 Studies to identify genetic AMD-
susceptibility variants have utilized all available techniques 
such as genome-wide linkage approaches (twins, sib pairs, 
and families)21–27 and case-control association studies. 
A table of replicated AMD-susceptibility genes is shown in 
Table 1. For the most part, studies have been limited to the 
study of the phenotypic extremes; that is, advanced cases 
or those with no signs of the condition, and case-control 
populations of extreme phenotypes. This is because it is 
reasonably achievable to ascertain these phenotypes. There 
are a few clinical caveats. Firstly, while it is straightforward 
to identify advanced AMD, often atrophy and neovascular 
disease coexist either in the same eye or in the fellow eye, 
and how to group these individuals is potentially problematic. 
Furthermore, it is less routine to rule out the presence of neo-
vascular AMD in an eye with apparent geographic atrophy. 
Since the presence of small drusen is almost universal in 
older individuals, it is somewhat arbitrary how few need to 
be present for an eye to remain a control.
Intermediate stages of AMD are more difficult to 
phenotype and require quantification of such endophenotypes 
such as drusen (size, number, distribution, area) and macular 
pigment epithelial changes (hypo-/hyper-, area) which are 
challenging and less well appreciated from the   perspective 
of disease staging. As such, very limited information is 
currently available regarding the genetic architecture of 
intermediate AMD.
early studies
Early studies concentrated on genome-wide linkage 
and familial association analyses (twins, sib pairs, and 
families).21–23 The first genetic locus for AMD was local-
ized in a single large pedigree to chromosome 1q.28 Later, 
a co-segregating variant in HMCN-1 (hemicentin-1) was 
identified.29 HMCN-1 lies in close proximity to the CFH 
(complement factor H) gene, discussed below. Meta-analysis 
of a number of linkage studies24 consistently identified this 
same locus and several other genomic regions which were 
later shown to harbor specific genetic variants. Others remain 
the subject of further investigation.25–27
Table 1 Replicated AMD-susceptibility genes
Gene Effect of minor allele on 
odds ratio of having AMD
CFH ↑
ARMS2 ↑
C2 ↓
C3 ↑
CFI ↑
ABCA1 ↑
LIPC ↑
CETP ↑
LPL ↑
Near TIMP3 ↑
Abbreviation: AMD, age-related macular degeneration.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Complement genes
The first well established specific genetic variant to be 
associated with advanced AMD was the single nucleotide 
polymorphism (SNP) rs1061170 (T1277C; Y402H) in the 
CFH gene.30–32 This finding has been replicated by numerous 
studies.33 Additional analyses of the RCA locus on chromo-
some 1q in which the gene resides have concluded that 
haplotypes encompassing both CFH34,35 and neighboring 
genes,36 acting independently or in concert with the Y402H 
change, confer increased risk of drusen formation and 
advanced AMD.33,37 Subsequent analyses of the complement 
pathway identified SNPs in other complement components: 
complement factors C2, CFB,38,39 C3,40,41 and CFI.42 CFH is 
a regulator of complement activation, dysfunction of which 
has been linked to retinal pathology.43
The challenges of 10q26
Early genome-wide linkage studies consistently identified 
an AMD susceptibility locus on chromosome 10q26.24,25 
A   combination of genotyping and direct sequencing of this 
region initially identified two SNPs, 6 kb apart, in high 
linkage disequilibrium in many Caucasian populations,44 that 
are strongly associated with advanced AMD, as follows.
•	 The rs10490924 (A69S) variant lies within the putative gene, 
LOC387715, now named ARMS2 (age-related maculopathy 
susceptibility 2).45,46 ARMS2 has no known function, and 
the predicted protein shows little homology with other 
proteins. ARMS2 is only present in higher primates, and 
mRNA transcripts can be detected in the retina. Whether the 
protein is translated is still debated. Immunohistochemical 
analyses have provided conflicting evidence localizing pro-
tein within the mitochondrion47 in the inner segment of the 
photoreceptor;48 the cytoplasm, among other locations. Most 
recently, an indel in ARMS2 has been reported that appears 
to affect translation of the protein and has been postulated 
to be the functional variant at the 10q26 locus.48
•	 The rs11200638 SNP resides in the promoter of the gene, 
HTRA1,49,50 a serine protease found in the retina (among 
other tissues). Preliminary, functional analyses suggest 
that the polymorphism at this position alters expression 
levels of the gene.49
The era of genome-wide SNP-association 
studies (GwAS)
Modern advances in genotyping technology have facilitated 
the high-throughput analysis of hundreds of thousands 
of single-  nucleotide polymorphisms on a single chip. 
In 2010, a consortium of researchers published the results 
of two independent GWASs with subsequent replication of 
positive findings. These studies identified several new genes 
associated with advanced AMD status.51,52 Of interest, this 
study implicated genes associated with lipid metabolism, 
  specifically the HDL pathway, ABCA1, LIPC, CETP, 
and LPL. Other replicated findings included significantly 
associated SNPs near the gene encoding TIMP3 (tissue 
inhibitor of metalloproteinase 3), which is involved in 
remodeling of the extracellular matrix in the retina.
Other genes
Associations in the genes APOE (apolipoprotein E),53–55 
ABCA4 (ATP-binding cassette A4),56,57 CX3CR1 (chemokine 
3 receptor 1),58,59 PON1,60 TLR4 (toll-like receptor 4),61 
ERCC6,62 ELOVL4,63,64 VLDLR (very low density 
lipoprotein receptor),65 fibulin-5,66 hemicentin-1,29 TLR3 
(toll-like receptor 3),67 C1q (complement factor C1q),68 VEGF 
  (vascular endothelial growth factor),65,69,70 SERPING1,71,72 
and LRP665 have been reported in single populations.
Pharmacogenetics in AMD
The identification of common genetic variants that 
  contribute significantly to the etiology of AMD has   garnered 
  interest in evaluating whether these same SNPs and other 
candidate genes may play a role in treatment response 
(pharmacogenetics).
Pharmacogenetics attempts to define the genetic variants 
that determine variable response to medication. The ultimate 
goal is to identify those who respond best and avoid adverse 
reactions. Garrod first recognized a familial or genetic ten-
dency to variability in drug response73 and hypothesized that 
drugs were metabolized by specific pathways of genes in 
which defects would result in differences in drug concentra-
tions and therefore drug effect. A large number of studies 
have now defined pharmacogenetic interactions in many 
biomedical fields. These include therapies for neurologi-
cal and psychiatric disorders,74–76 asthma,77 cardiovascular 
disease,78 and cancer.79,80
Initial studies in AMD have focused on three different 
treatments: Age-Related Eye Disease Study (AREDS) 
supplementation, photodynamic therapy (PDT), and anti-
VEGF therapy. In all instances, studies to date have been 
limited to retrospective analyses.
Anti-veGF agents
In one retrospective study, 86 patients being treated 
with bevacizumab (Avastin™) alone were evaluated for 
associations between treatment response and common Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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polymorphisms in the genes CFH and ARMS2. Patients 
homozygous for both CFH risk alleles (CC) had worse visual 
outcomes than those with the CFH TC and TT genotypes.81 
In a similar retrospective analysis, but involving 156 patients 
who were receiving ranibizumab, the same authors were able 
to replicate this finding.82 These studies were well conducted; 
however, the associations do not necessarily imply causality 
and there may have been additional confounders.
AReDS supplements
The AREDS was an 11-center National Institutes of Health-
funded study initiated in 1992 with 4757 participants. It 
included an 8-year randomized control trial which established 
that a combination of zinc and antioxidants (beta-carotene, 
vitamin C, and vitamin E) produced a 25% reduction in 
development of advanced AMD and a 19% reduction in 
severe vision loss in individuals determined to be at high risk 
of developing the advanced forms of the disease.6 Conversely, 
22% of participants receiving antioxidants and zinc had a 
15-letter decrease in visual acuity despite treatment. Use of 
these oral supplements is now current standard of practice 
in the United States. Indeed, they remain the only therapy 
for early, intermediate,6 and dry AMD.83
A recent evaluation of the AREDS cohort found evidence 
of an interaction between the CFH genotype and treatment 
with antioxidants plus zinc when compared with placebo. This 
interaction appears to have arisen because supplementation 
was associated with a greater reduction in AMD progression 
(68%) in those with the low risk TT genotype compared with 
those with the high risk CC genotype (11%).
These results may imply that the strong genetic 
predisposition to AMD conferred by the CC genotype limits the 
benefits available from zinc and antioxidants (beta-carotene, 
vitamin C, and vitamin E).84 In this pharmacogenetics study, 
the authors evaluated whether known AMD-susceptibility 
genotypes in those who at entry into the study had early to 
intermediate AMD and progressed to advanced disease were 
associated with treatment assignment. Previously, these same 
genes had been reported to be independently associated with 
progression to advanced AMD.85,86 There is good biological 
plausibility to support a possible role for CFH. Evidence 
supports the assertion that CFH protein dysfunction results in 
excessive inflammation and tissue damage of the type involved 
in the pathogenesis of AMD.9,20 Inflammation is known to 
intensify oxidative stress,21 and since AREDS supplements are 
thought to have an antioxidant effect,22–25 it seems reasonable 
to assume that CFH polymorphisms could play a role in 
treatment response.13,14
PDT
PDT was until recently the most widely used therapy for 
neovascular AMD and still retains a role for individuals in 
whom anti-VEGF agents are contraindicated.87 PDT to the 
macula induces thrombosis of neovascular vessels (choroidal 
neovascularization) which have been photosensitized by the 
administration of verteporfin.88 Efficacy was originally estab-
lished in a series of randomized control trials including the 
TAP (Treatment of Age-Related Macular Degeneration with 
Photodynamic Therapy), VIP (Visudyne in Photodynamic 
Therapy), and Visudyne in Minimally Classic Choroidal 
  Neovascularization studies.87 Considerable variability in 
response is observed with PDT and may vary by ethnicity.89 
In an attempt to identify whether genetic influences are 
involved, a set of variants in genes associated with throm-
bosis were retrospectively evaluated in two studies (84 and 
90 subjects). Patients were divided into those that were 
PDT “responders” and those that were “nonresponders” 
(3-month follow-up). Patients were genotyped for factor 
V G1691A, prothrombin G20210A, factor XIII-A G185T, 
methylenetetrahydrofolate reductase C677T, methionine 
synthase A2756G, and methionine synthase reductase A66G. 
“Nonresponse” was more frequent in those with the hyperfi-
brinolytic G185T gene polymorphism of factor XIII-A, and 
response was associated with those with the thrombophilic 
factor V 1691A and prothrombin 20210A alleles.89–91
As this article is being written, several other prospective 
pharmacogenetic studies are nearing completion. Cumula-
tively, these should provide further significant insights into 
those variants involved with treatment response in AMD.
Predicting the risk of developing 
advanced AMD
The idea of employing a risk assessment algorithm to identify 
individuals at risk of developing AMD is attractive. The fact 
that drusen, the hallmark of the condition, appear prior to the 
development of vision loss offers an unusually useful clinical 
feature that might be combined with genetic and environmen-
tal risk factors to give an accurate risk assessment. Several 
such models have been proposed. Seddon et al described 
a model derived from the AREDS study population that 
included all these factors using the AREDS clinical AMD 
grading scale.92 In the model, points are assigned for the 
risk factors in their model to determine an individual’s risk 
score. Zanke et al described a model that gives a lifetime risk 
estimate based on genetics and environmental factors,93 and 
recently Chen et al proposed a model that examined risk of 
bilateral involvement.94 There is no conclusive   evidence that Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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genetic variants assist in predicting progression of disease 
once advanced AMD is established. One study found no asso-
ciation of progression of geographic atrophy with variants 
in the CFH, C3, and ARMS2 genes.95 A second study found 
no association of progression with variants in CFH, C2, C3, 
and CFI, but did note a nominal association with ARMS2.96
Concluding remarks
AMD is a major health burden and one that is rapidly   growing 
as the population of the Western world ages, en masse. Although 
the introduction of anti-VEGF agents has revolutionized 
outcomes for those with the less   common neovascular form of 
AMD, there is limitation to the effectiveness of these regimens. 
There is currently neither effective treatment for geographic 
atrophy nor for earlier stages of disease. Dissecting the genetic 
etiology of the condition holds substantial promise for the 
identification of new avenues for therapeutic development. 
It is likely that conventional genome-wide and candidate 
gene approaches may have reached their limit to resolve new 
variants. Genome-wide strategies are not themselves redundant 
but will be superseded by next-generation technology such as 
whole Exmore and full genome sequencing.97 Furthermore, the 
analysis of individuals with intermediate AMD phenotypes 
and the use of extended pedigrees with carefully quantified 
endophenotypes offer the opportunity to investigate less 
common, rarer, and private mutations, otherwise largely 
unidentifiable using case-control populations.
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